Skip to content

Ketogenic Diet in Women With Lipedema

Effect of a Low-Carbohydrate, High-Fat (LCHF) Ketogenic Diet on Adipose Tissue Hormones, Oxidative Stress, Inflammation, Lymphatic and Angiogenic Factors, Metabolomics, Symptoms, and Quality of Life in Women With Lipedema

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07530341
Enrollment
121
Registered
2026-04-15
Start date
2020-02-20
Completion date
2023-12-31
Last updated
2026-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipedema, Overweight and Obesity

Keywords

lipedema, ketogenic diet, inflammation, metabolomics, angiogenesis, personalized nutrition, lymphatic function

Brief summary

Lipedema is a chronic fat tissue disorder that usually affects the lower limbs, excluding the feet. Clinical symptoms of lipedema include a noticeable disproportion between the upper and lower body, a tendency to easy bruising, and pain in the fatty tissue. It is a common disorder that occurs almost exclusively in women, potentially affecting around 11% of the adult population worldwide. The disease, especially in its advanced stages, has negative psychosocial consequences, leading to social isolation or depression, among other issues. The etiology of the disease is unknown, but genetic, hormonal, and inflammatory factors are likely involved in its pathogenesis. This disorder is characterized by the presence of low-grade inflammation in the fat tissue. The use of reduction diets combined with physical activity or bariatric surgery does not constitute an effective therapeutic approach for lipedema. Recent interventional studies show that an anti-inflammatory ketogenic diet leads to a reduction in leg volume and lipedema symptoms, including pain in the extremities. This study aims to evaluate clinical, metabolic, inflammatory, and vascular characteristics in women with lipedema and to assess potential changes associated with dietary intervention - 7 months of ketogenic diet (low carbohydrate, high fat). Participants undergo clinical, laboratory, and patient-reported outcome assessments to evaluate anthropometric parameters, quality of life, and selected biomarkers. The findings are expected to improve understanding of the biological mechanisms underlying lipedema and to support the development of targeted therapeutic strategies.

Detailed description

A total of 121 women were invited to participate in the study. The study group consisted of patients from the Angiology Outpatient Clinic at Wroclaw Medical University in Poland with the diagnosis of lipedema made by an angiologist (n=66). The control volunteer group was composed of women with overweight or obesity (body mass index, BMI= 25 kg/m2) who were not affected by lipedema (n=55). All participants recruited to the study underwent following procedures at the beginning and at the end of the study: 1. Measurement of anthropometric parameters: * height - A TANITA HR-001 growth meter (Tanita, Tokyo, Japan) * weight and body composition parameters (body fat, lean body mass, body water, visceral fat) - A TANITA MC-780MA (Tanita, Tokyo, Japan) * waist, hip and leg circumferences (at 4 cm intervals from the ankle to the groin on the side of the leg) - standard tape measure to the nearest 1 cm 2. Questionnaires: * assessment of pain level in the leg - visual analogue scale (VAS) * assessment of psychological status, symptoms and quality of life: * The World Health Organization Disability Assessment Schedule (WHO-DAS II) * Beck's Depression Inventory - II (BDI-II) * The Hospital Anxiety and Depression Scale (HADS) * symptoms of the lower extremities (LYMQOL) * distress symptoms (GHQ28) * quality of life (SF-36) * assessment of food consuming - Food Frequency Questionnaire (FFQ) 3. Blood samples collection: • collection of approximately 25 ml of peripheral blood for laboratory tests * adipose tissue hormones: adiponectin, leptin, resistin, visfatin, and vaspin * oxidative stress markers: lipid peroxidation (TBARS)TBARS, 8-iso-prostaglandin F2α concentration, protein carbonyl content, serum total antioxidant capacity (TAC), superoxide dismutase (SOD) activity, catalase (CAT) activity, serum antioxidant vitamins (C, A and E) * angiogenic and lymphangiogenic factors: VEGF-A, VEGF-C, VEGF-D, angiopoietin-2, sICAM-1, sVCAM-1, P-selectin * endothelial adhesion molecules: sVCAM-1, sICAM-1, P-selectin * inflammatory cytokines: TNF-α, IL-1β, IL-8, IL-10, IL-13, CRP * targeted metabolomics: selected eicosanoids, endocannabinoids, and nitric oxide metabolites 4. Fat samples collection from the subcutaneous fatty tissue • collection of a drop subcutaneous fat from the thigh for metabolomic tests: * angiogenic and lymphangiogenic factors: VEGF-A, VEGF-C, VEGF-D, angiopoietin-2, sICAM-1, sVCAM-1, P-selectin * endothelial adhesion molecules: sVCAM-1, sICAM-1, P-selectin * inflammatory cytokines: TNF-α, IL-1β, IL-8, IL-10, IL-13 * targeted metabolomics: selected eicosanoids, endocannabinoids, and nitric oxide metabolites Of the original study population, 48 patients completed the study (28 in the lipedema group and 24 with overweight/obesity).

Interventions

BEHAVIORALLow carbohydrate high fat (ketogenic) diet with anti-inflammatory properties

The interventional diet structure was similar to a typical ketogenic diet, with less than 50 g of carbohydrates per day. The diet was designed as a Mediterranean style with many food products with anti-inflammatory properties such as antioxidants, unsaturated fatty acids, herbs, spices, tea and coffee. The diet was reduced in saturated fatty acids and processed foods. All the involved participants received the personalized caloric-restricted low-carbohydrate high-fat (ketogenic) diet, based on the patient's preferences. The daily energy intake was divided into 3 meals, consisting of a source of protein, fat, and vegetable additives. They received individual 7-day meal plans to repeat for 7 months with recipes and a shopping list. The personalization of the dietary plans aimed to increase compliance with the diets. Additionally, each patient received detailed dietary recommendations that facilitated adherence to the dietary plan.

Sponsors

Wroclaw Medical University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Experimental Arm Control Arm

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* consent to participate in the study * diagnosis of lipedema proved by an angiologist * overweight or obesity based on BMI\>25 kg/m2

Exclusion criteria

* pregnancy and period of 6 months after pregnancy, * breastfeeding, * diagnosis of lymphedema, * edema in the course of chronic vein insufficiency or heart failure, * diabetes mellitus, * kidney or liver failure, * hormonally unbalanced thyroid disease, * cancer * implanted cardiac devices (cardiac pacemaker, implantable cardioverter-defibrillator, resynchronization therapy) * metal implants

Design outcomes

Primary

MeasureTime frameDescription
Change in leg circumferencesUp to 7 monthsChanges in leg circumferences between 2 timepoints (baseline and end of study)

Secondary

MeasureTime frameDescription
Change in body weightUp to 7 monthsChange in body weight in kilograms measured using bioelectrical impedance analysis between 2 timepoints (baseline and end of study).
Change in body fatUp to 7 monthsChange in body fat percentage (%) measured using bioelectrical impedance analysis between 2 timepoints (baseline and end of study).
Change in lean body massUp to 7 monthsChange in lean body mass in kilograms measured using bioelectrical impedance analysis between 2 timepoints (baseline and end of study).
Change in body waterUp to 7 monthsChange in body water in kilograms measured using bioelectrical impedance analysis between 2 timepoints (baseline and end of study).
Change in visceral fat levelUp to 7 monthsChange in visceral fat level measured using bioelectrical impedance analysis between 2 timepoints (baseline and end of study). Visceral fat level is measured on a scale from 1 (lowest level) to 20 (highest level).
Change in disability levelUp to 7 monthsChange in disability level measured using the World Health Organization Disability Assessment Schedule II (WHO-DAS II) total score between 2 timepoints (baseline and end of study).
Change in depressive symptomsUp to 7 monthsChange in depressive symptoms measured using the Beck Depression Inventory-II (BDI-II) total score between 2 timepoints (baseline and end of study).
Change in anxiety and depression symptomsUp to 7 monthsChange in anxiety and depression symptoms measured using the Hospital Anxiety and Depression Scale (HADS) total score between 2 timepoints (baseline and end of study).
Change in lower extremity symptomsUp to 7 monthsChange in lower extremity symptoms measured using the Lymphedema Quality of Life Questionnaire (LYMQOL) total score between 2 timepoints (baseline and end of study).
Change in psychological distressUp to 7 monthsChange in psychological distress measured using the General Health Questionnaire (GHQ-28) total score between 2 timepoints (baseline and end of study).
Change in quality of lifeUp to 7 monthsChange in quality of life measured using the Short Form Health Survey (SF-36) total score between 2 timepoints (baseline and end of study).
Change in pain intensity in the legsUp to 7 monthsChange in pain intensity assessed using the Visual Analogue Scale (VAS) between 2 timepoints (baseline and end of study). Pain intensity is measured using the VAS, a 10-cm scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.
Change in leptin concentrationUp to 7 monthsChange in serum leptin concentration \[ng/ml\] measured between 2 timepoints (baseline and end of study).
Change in adiponectin concentrationUp to 7 monthsChange in serum adiponectin concentration \[ng/ml\] measured between 2 timepoints (baseline and end of study).
Change in resistin concentrationUp to 7 monthsChange in serum resistin concentration \[pg/ml\] measured between 2 timepoints (baseline and end of study).
Change in vaspin concentrationUp to 7 monthsChange in serum vaspin concentration \[pg/ml\] measured between 2 timepoints (baseline and end of study).
Change in visfatin concentrationUp to 7 monthsChange in serum visfatin concentration \[ng/ml\] measured between 2 timepoints (baseline and end of study).
Change in TNF-α concentrationUp to 7 monthsChange in serum tumor necrosis factor-alpha (TNF-α) concentration measured between 2 timepoints (baseline and end of study).
Change in IL-1β concentrationUp to 7 monthsChange in serum interleukin-1 beta (IL-1β) concentration measured between 2 timepoints (baseline and end of study).
Change in IL-8 concentrationUp to 7 monthsChange in serum interleukin-8 (IL-8) concentration measured between 2 timepoints (baseline and end of study).
Change in IL-10 concentrationUp to 7 monthsChange in serum interleukin-10 (IL-10) concentration measured between 2 timepoints (baseline and end of study).
Change in IL-13 concentrationUp to 7 monthsChange in serum interleukin-13 (IL-13) concentration measured between 2 timepoints (baseline and end of study).
Change in CRP concentrationUp to 7 monthsChange in serum C-reactive protein (CRP) concentration measured between 2 timepoints (baseline and end of study).
Change in TBARS concentrationUp to 7 monthsChange in serum thiobarbituric acid reactive substances (TBARS) concentration \[µmol/l\] measured between 2 timepoints (baseline and end of study).
Change in 8-iso-prostaglandin F2α concentrationUp to 7 monthsChange in serum 8-iso-prostaglandin F2α concentration \[pg/mL\] measured between 2 timepoints (baseline and end of study).
Change in protein carbonyl contentUp to 7 monthsChange in serum protein carbonyl content \[nmol/mg protein\] measured between 2 timepoints (baseline and end of study).
Change in total antioxidant capacityUp to 7 monthsChange in serum total antioxidant capacity (TAC) \[mmol Trolox eqiv./l\] measured between 2 timepoints (baseline and end of study).
Change in SOD activityUp to 7 monthsChange in serum superoxide dismutase (SOD) \[U/ml\] measured between 2 timepoints (baseline and end of study).
Change in CAT activityUp to 7 monthsChange in serum catalase (CAT) \[U/ml\] measured between 2 timepoints (baseline and end of study).
Change in vitamin C concentrationUp to monthsChange in serum vitamin C concentration \[µmol/l\] measured between 2 timepoints (baseline and end of study).
Change in vitamin A concentrationUp to 7 monthsChange in serum vitamin A concentration \[µmol/l\] measured between 2 timepoints (baseline and end of study).
Change in vitamin E concentrationUp to 7 monthsChange in serum vitamin E concentration \[µmol/l\] measured between 2 timepoints (baseline and end of study).
Change in VEGF-A concentrationUp to 7 monthsChange in serum and subcutaneous tissue VEGF-A concentration \[pg/mL\] measured between 2 timepoints (baseline and end of study).
Change in VEGF-C concentrationUp to 7 monthsChange in serum and subcutaneous tissue VEGF-C concentration \[pg/mL\] measured between 2 timepoints (baseline and end of study).
Change in VEGF-D concentrationUp to monthsChange in serum and subcutaneous tissue VEGF-D concentration \[pg/mL\] measured between 2 timepoints (baseline and end of study).
Change in angiopoietin-2 concentrationUp to 7 monthsChange in serum and subcutaneous tissue angiopoietin-2 concentration \[pg/mL\] measured between 2 timepoints (baseline and end of study).
Change in sICAM-1 concentrationUp to 7 monthsChange in serum and subcutaneous tissue soluble ICAM-1 (sICAM-1) concentration \[ng/mL\] measured between 2 timepoints (baseline and end of study).
Change in sVCAM-1 concentrationUp to 7 monthsChange in serum and subcutaneous tissue soluble VCAM-1 (sVCAM-1) concentration \[ng/mL\] measured between 2 timepoints (baseline and end of study).
Change in P-selectin concentrationUp to 7 monthsChange in serum and subcutaneous tissue p-selectin concentration \[pg/mL\] measured between 2 timepoints (baseline and end of study).
Change in eicosanoids concentrationsUp to 7 monthsChange in serum/plasma concentrations of selected eicosanoids measured between 2 timepoints (baseline and end of study) using targeted metabolomics (ng/mL): * 13,14-dihydro Prostaglandin E1 \[ng/mL\] * 15-deoxy-Δ12,14-Prostaglandin J2 \[ng/mL\] * Prostaglandin D2 \[ng/mL\] * Prostaglandin E2 \[ng/mL\] * 6-keto Prostaglandin F1α \[ng/mL\] * Prostaglandin F2α \[ng/mL\] * Leukotriene B4 \[ng/mL\] * Thromboxane B2 \[ng/mL\]
Change in endocannabinoids concentrationsUp to 7 monthsChange in serum/plasma concentrations of selected endocannabinoids concentrations measured between 2 timepoints (baseline and end of study) using targeted metabolomics (ng/mL): * Arachidonoyl ethanolamide (AEA) \[ng/mL\] * Oleoyl ethanolamide (OEA) \[ng/mL\] * Palmitoyl ethanolamide (PEA) \[ng/mL\] * 1-Arachidonoyl glycerol (1-AG) \[ng/mL\] * 2-Arachidonoyl glycerol (2-AG) \[ng/mL\]
Change in nitric oxide metabolites concentrationsUp to 7 monthsChange in serum/plasma concentrations of selected nitric oxide metabolites concentrations measured between 2 timepoints (baseline and end of study) using targeted metabolomics (µmol/L): * asymmetric dimethylargininine (ADMA) * symmetric dimethylargininine (SDMA)

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026